Columbia Laboratories, Inc. Signs U.S. License and Supply Agreement with ASCEND Therapeutics, Inc. to Market PROCHIEVE(R) 4% Progesterone Gel

LIVINGSTON, N.J.--(BUSINESS WIRE)--Columbia Laboratories, Inc. (NASDAQ: CBRX) today announced that it has signed an exclusive, five year license and supply agreement with Ascend Therapeutics, Inc., for the Company’s PROCHIEVE ® 4% progesterone gel, currently indicated and FDA-approved for the treatment of secondary amenorrhea (secondary amenorrhea is lack of periods for six or more months in a woman who has already started menstruation and who is not pregnant, lactating, or in menopause).

Back to news